Trial Profile
A Phase 1/2, Open-label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Bavdegalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ARDENT
- Sponsors Arvinas
- 10 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2023 Results (As of Dec 20, 2022) presented at the 48th European Society for Medical Oncology Congress
- 22 Oct 2023 According to an Arvinas media release, the company will host a conference call to discuss results from this trial.